valeant pharmaceuticals

This weekend's Barron's cover story looks at why the buyback boom is bullish for investors. Other featured articles offer a dozen elite dividend picks and ask whether a robot can build the perfect portfolio. Also, the prospects for a supermarket operator, a networking specialist...

Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included top semiconductor stocks and the e-commerce leader. Bearish calls featured an electric vehicle giant and a video streaming leader. The bull run is now officially nine years old and there...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced on Monday that three senior executives will be leaving the company. The executives that will be leaving the company include: Valeant's ex CFO Rob Rosiello, who stepped down in August but remained with the company since. Ari...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) stock has tumbled more than 30 percent and hit a new 52-week low of $13.77 before recovering above the $15 per share level. Investors and traders dumped Valeant's stock after the company's third quarter earnings report fell short of Wall...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is reportedly shopping for buyers to acquire its Salix unit for an expected $8.5 billion and additional royalty payments in the future. Valeant is plagued with debt, causing some concern among shareholders so any cash infusion would certainly ease...

Upcoming earnings highlights include the latest results from two generic pharmaceutical giants. Wall Street analysts are looking for earnings growth from just one of them. However, sequentially higher revenues are anticipated from both companies. On Tuesday, international generic pharmaceutical...

Featured stories this weekend in Barron's ponder the prospects for a financial-exchange operator, an automotive electronics maker and a consumer products company. This issue also offers ETF picks from a panel of pros and picks from the Sohn Conference. Other articles discuss the significance of...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) spiked higher by more than 6 percent early Friday morning following reports the company is close to naming a new CEO. According to The Wall Street Journal, Valeant is finalizing a contract with Perrigo Company plc (NYSE: PRGO)'s Chief Executive...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) hit a new 52-week low of $25.75 on Thursday after Canadian authorities said the company is in breach of regulations. Valeant Pharmaceuticals is based in Laval, Quebec. The provincial regulator, the Autorite Des Marches Financiers, issued...

Featured stories this weekend in Barron's ponder the prospects for a package delivery giant, a Dublin-based packaging company and a leading biotech company. Other featured articles include the annual ranking of the best online brokers. The cover story presents the annual list of the 30 best CEOs...

Regulators' involvement with Valeant Pharmaceuticals Intl Inc (NYSE: VRX) could last quite a while, according to John P. Gavin, CFA, founder and CEO of Probes Reporter, the research firm that broke Monday's news of an undisclosed SEC investigation into the Canadian pharmaceuticals company...

Democratic Presidential candidate Hillary Clinton released a new video ad on Monday directly attacking Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s drug pricing policies. Clinton's video ad, which was uploaded to her YouTube profile, was viewed just 200 times by mid-Tuesday morning...